{"id":"W2154753744","doi":"10.1093/annonc/mdu205","title":"A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":221,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University; University of Toronto; University of Alberta","funders":"","keywords":"Tremelimumab; Medicine; Tolerability; Gemcitabine; Internal medicine; Oncology; Pancreatic cancer; Chemotherapy; Gastroenterology; Cancer; Adverse effect; Immunotherapy; Ipilimumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001520849,0.00159295,0.00247912,0.0006451049,0.000474859,0.001296943,0.001040791,0.001253737,0.004231039],"category_scores_gemma":[0.001179464,0.0008342973,0.001762339,0.0006792779,0.001185972,0.001383813,0.0005661506,0.005191914,0.001319683],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001095503,"about_ca_system_score_gemma":0.001460901,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001012931,"about_ca_topic_score_gemma":0.002804975,"domain_scores_codex":[0.999514,0.0002206829,0.00002508332,0.00009554323,0.00003294353,0.0001117327],"domain_scores_gemma":[0.9992837,0.0001190714,0.0001183762,0.0000735483,0.00003015091,0.0003751327],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8397414,0.04656432,0.003039803,0.0007075968,0.001383545,0.0001903169,0.0003123069,0.002872865,0.0194285,0.0003073436,0.003389288,0.08206275],"study_design_scores_gemma":[0.7248768,0.2643184,0.005788454,0.00002771367,0.0004648803,0.0001675269,0.00006264149,0.001119043,0.001512681,0.0001892055,0.001441716,0.00003102703],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9938347,0.001328274,0.0003966272,0.0005983952,0.0001918506,0.001373316,0.0006461299,0.0001204958,0.001510231],"genre_scores_gemma":[0.9894553,0.001784041,0.001612157,0.0008860402,0.000200507,0.001713123,0.001780419,0.00004813755,0.002520256],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004231039,"threshold_uncertainty_score":0.0141542,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04119301553983473,"score_gpt":0.3675221896947738,"score_spread":0.3263291741549391,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}